Healthcare · 13.3

Biotechnology

Quantified news impact based on deduplicated, quality-reviewed events in a single 200-day window.

Average net impact+24weighted per event

Average gross impact30absolute weighted average

Events28same period

Confidence76%model average

Raw intensity58before weighting

Previous period0net impact

Gross changeInsufficient base

Diffusion speed0.1 / day

Concentration5%

Direction disagreement19%

Source independence100%12 sources

IMPACT TREND

200-day effective impact

Positive 24 · Negative 2 · Mixed 2

+240-24

15 Jan0 events

1 Feb0 events

18 Feb0 events

6 Mar0 events

23 Mar0 events

9 Apr0 events

25 Apr0 events

12 May0 events

29 May0 events

14 Jun0 events

1 Jul0 events

+24

18 Jul28 events

Current periodPrevious period

TIME HORIZON

Impact duration

Immediate0%0 cumulative effective impact

Short term37%305 cumulative effective impact

Medium term51%421 cumulative effective impact

Long term13%105 cumulative effective impact

CO-IMPACT

Related industries

EVENT EVIDENCE

Events ranked by effective impact

Page 2 of 3 · 28 events

Macro3

Macro28 Jul, 17:18positive

Beijing Releases Hepatitis Prevention Action Plan, Targeting 95% Full Vaccination Coverage for Children by

Beijing has released a hepatitis prevention action plan for 2026-2030, setting targets for 2030. These include 95% full vaccination coverage for children for hepatitis A and B, 90% timely first-dose hepatitis B vaccination for newborns, a mother-to-child transmission rate below 1%, an acute hepatitis B incidence rate no higher than 1 per 100,000, and a diagnosis rate for chronic hepatitis B patients of at least 80%.

Effective: +28
Intensity: 60
Confidence: 80%
Horizon: Medium term

Macro29 Jul, 19:58positive

Shenzhen Aims for Strategic Emerging Industries to Hit 2.3 Trillion Yuan, 45% of GDP by 2030

Shenzhen's municipal authorities have issued a plan to develop new quality productive forces and cultivate strategic emerging industries and future industries. By 2030, the city aims for the value-added of strategic emerging industries to reach RMB 2.3 trillion, accounting for 45% of its gross domestic product, with advanced manufacturing as the backbone of a modern industrial system.

Effective: +26
Intensity: 70
Confidence: 60%
Horizon: Long term

Macro29 Jul, 18:34positive

Shanghai Guotou Xian Dao Fund: 900 Billion Yuan Mother Funds Invest 565 Billion Yuan

At the 2026 Science and Technology Innovation Industry Integration Development Conference, Wen Zhi, General Manager of Shanghai Guotou Xian Dao Fund, stated that the three major leading industry mother funds total RMB 900 billion, with cumulative investment decisions of RMB 565 billion and disbursements of RMB 340 billion, leveraging over RMB 2.5 trillion in social capital. Direct investments exceed 70% into early-stage and small enterprises, while 55 sub-funds allocate over 80% to such projects. Wen Zhi outlined four practices addressing the challenges of early-stage investing, supported by policies from 2025 and 2026.

Effective: +25
Intensity: 50
Confidence: 75%
Horizon: Long term

Industries1

Industries29 Jul, 20:43positive

China's Pharmaceutical Distribution Market Reaches 1.54 Trillion RMB in First Half of 2026, Up 4%

In the first half of 2026, China's pharmaceutical distribution industry recorded a market size of about 1.54 trillion RMB, up approximately 4% year on year. The sector is accelerating its transformation toward intensification and specialization. High-end cold chain logistics has emerged as a profit growth driver, with leading enterprises deploying multi-temperature zone smart warehouses nationwide. As digital and intelligent upgrades become widespread, AI scheduling, unmanned warehouses, and full-chain temperature and humidity tracking have become standard.

Effective: +22
Intensity: 55
Confidence: 70%
Horizon: Short term

Companies6

Companies27 Jul, 17:25positive

Dutch Argenx SE Acquires Forte Biosciences for $2.2 Billion; Shares Surge 39%

Forte Biosciences shares surged nearly 39% in pre-market trading after the company agreed to be acquired by Dutch biotech firm Argenx SE for $2.2 billion in a premium deal. The acquisition represents a significant premium to Forte's recent market price.

Effective: +30
Intensity: 60
Confidence: 80%
Horizon: Short term

Companies27 Jul, 15:48positive

Emerge Bioscience, a Jianyou Subsidiary, Receives FDA Approval for Insulin Aspart Injection

Jianyou Co. , Ltd.' s wholly owned subsidiary Emerge Bioscience Pte. has obtained U. S. Food and Drug Administration (FDA) approval for its Biologics License Application (BLA) for insulin aspart injection. The product is indicated to improve glycemic control in adult and pediatric patients with diabetes.

Effective: +30
Intensity: 60
Confidence: 80%
Horizon: Medium term

Companies27 Jul, 21:29positive

Kelun-Biotech’s Dual-Load ADC Drug SKB565 Approved for Clinical Trials in Advanced Solid Tumors

Kelun-Biotech, a controlled subsidiary, has received clinical trial approval from the National Medical Products Administration’s Center for Drug Evaluation for its novel dual-load antibody-drug conjugate (ADC) SKB565, intended for advanced solid tumors. This is the first dual-load ADC drug from Kelun-Biotech to enter the clinical stage.

Effective: +28
Intensity: 60
Confidence: 75%
Horizon: Long term

Companies27 Jul, 16:47positive

Hengrui Medicine's SHR-4375 Injection Gets FDA Orphan Drug Designation for Pancreatic Cancer

Hengrui Medicine announced on July 27 that its SHR-4375 injection has received orphan drug designation from the U. S. Food and Drug Administration for the treatment of pancreatic cancer. Orphan drugs are intended for rare diseases, and the designation may provide development incentives.

Effective: +27
Intensity: 60
Confidence: 80%
Horizon: Short term

Companies31 Jul, 20:23negative

Alnylam Q2 2026 Product Net Revenue $1.172 Billion, Shares Slump 28% on Guidance Cut

Alnylam reported Q2 2026 product net revenue of $1.172 billion, up 74% year-on-year. Amvuttra sales exceeded $1 billion for the first time, reaching $1.012 billion, up 106%. However, the company trimmed its full-year TTR pipeline sales guidance to $4.2-4.5 billion from $4.4-4.7 billion, sending shares down 28% to a market cap below $30 billion. The company highlighted slowing growth in second-line Amvuttra use in the US, with 80% of new starts being first-line.

Effective: -25
Intensity: 45
Confidence: 75%
Horizon: Short term

Companies27 Jul, 17:13positive

China Biopharmaceutical and Tempo Scan Form Indonesia JV, China Holds 51% Stake

China Biopharmaceutical has signed a joint venture agreement with Indonesia-listed Tempo Scan to establish PT Tempo CTTQ Biopharmaceutical Indonesia (TCBI). China Biopharmaceutical holds a 51% stake, with Tempo Scan holding 49%. TCBI will combine Tempo Scan's local expertise with China Biopharmaceutical's R&D strengths to focus on drug registration, clinical development, and commercialization. Several products have received local regulatory approval or are under review, with the first specialty drugs expected to launch after regulatory clearance and operational preparations.

Effective: +23
Intensity: 50
Confidence: 80%
Horizon: Long term